Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced a definitive agreement for a registered direct offering expected to generate approximately $4.4 million in gross proceeds. The company will sell 2,135,923 shares of common stock, or pre-funded warrants in lieu thereof, at $2.06 per share. Concurrently, Lantern disclosed a private placement of unregistered warrants and revealed plans to create an independent business entity composed of its AI platform, withZeta.ai, and related technologies and personnel.
The move comes as Lantern seeks to unlock value from its proprietary AI capabilities. withZeta.ai, described as a multi-agentic AI co-scientist platform, is already commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. By spinning off this asset into a separate entity, Lantern aims to focus on its core clinical pipeline while allowing the AI platform to operate independently and potentially attract its own investment and partnerships.
Lantern’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
The implications of this announcement are significant for both Lantern Pharma and the broader biomedical industry. For Lantern, the $4.4 million offering provides immediate capital to advance its clinical programs and support the spin-off of its AI unit. The creation of an independent entity for withZeta.ai could enable the platform to scale more rapidly, attract customers beyond Lantern’s internal use, and potentially generate licensing or partnership opportunities. For the industry, the move reflects a growing trend where AI-driven drug discovery platforms are being commercialized as standalone services, offering researchers access to advanced computational tools without the need for in-house development.
Lantern’s AI platform, RADR, has been central to its approach of transforming cancer therapy development through machine learning. The decision to spin off withZeta.ai suggests confidence in its commercial viability and could set a precedent for other AI-focused biotechs. If successful, this model could accelerate the adoption of AI in drug development, reducing costs and timelines for bringing new therapies to market.
For investors and industry observers, the offering and spin-off represent a strategic pivot that may enhance shareholder value by separating the higher-risk clinical pipeline from the more predictable revenue-generating AI platform. The registered direct offering structure also indicates institutional interest, as it allows for a quicker capital raise compared to traditional public offerings.
To view the full press release, visit https://ibn.fm/6Dy4I. More information about Lantern Pharma is available in the company’s newsroom at https://ibn.fm/LTRN.
